

01-02-01

A

Please type a plus (+) inside this box - ☒

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

12/28/00

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

8449-134

Total Pages

197

First Named Inventor or Application Identifier

PRAMOD K. SRIVASTAVA

Express Mail Label No.

EL 501 635 817 US

**APPLICATION ELEMENTS**
See MPEP chapter 600 concerning utility patent application contents.ADDRESS TO: Assistant Commissioner for
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☒ Specification (including Table of Contents) [Total Pages 102]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description of the Invention (including drawings, *if filed*)
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 91]
4. ☒ Oath or Declaration (unexecuted) [Total Sheets 2]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ **DELETION OF INVENTORS(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. ☐ Incorporation By Reference *(useable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program *(Appendix)*
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☒ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: 09/668,724 filed September 22, 2000.

18. CORRESPONDENCE ADDRESS☒ Customer Number or Bar Code Label

20583

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PENNIE & EDMONDS LLP
 COUNSELLORS AT LAW
 1155 Avenue of the Americas
 New York, N.Y. 10036-2711
 (212) 790-9090

ATTORNEY DOCKET NO. 8449-134Date: December 28, 2000

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): PRAMOD K. SRIVASTAVA

Executed on: Unexecuted

Title of Invention: ALPHA (2) MACROGLOBULIN RECEPTOR AS A HEAT SHOCK PROTEIN RECEPTOR AND
 USES THEREOF

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	116	-20	96	\$18.00 each	\$ 1,728.00
Independent	29	-3	26	\$80.00 each	\$ 2,080.00
Minimum Fee					\$ 710.00
Multiple Dependency Fee If Applicable (\$270.00)					\$ 270.00
Total					\$ 4,788.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					- \$ 0.00
Total Filing Fee					\$ 4,788.00

- ☐ Priority of application no. filed on in is claimed under 35 U.S.C. § 119.
☐ The certified copy of the priority application has been filed in application no. filed
☒ Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. 09/668,724 filed on September 22, 2000.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

32605

Adriane M. Antler
 PENNIE & EDMONDS LLP

(Reg. No.)

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

01/04/2001 EGBRECH1 00000052 161150 09750972

01 FC:101 710.00 CH
 02 FC:102 2080.00 CH
 03 FC:103 1728.00 CH
 04 FC:104 270.00 CH

ALPHA (2) MACROGLOBULIN RECEPTOR AS A HEAT SHOCK PROTEIN
RECEPTOR AND USES THEREOF

5

TABLE OF CONTENTS

10	1. INTRODUCTION	1
	2. BACKGROUND OF THE INVENTION	1
	2.1. HEAT SHOCK PROTEINS	1
	2.2. IMMUNOGENICITY OF HSP-PEPTIDE COMPLEXES	2
15	3. SUMMARY OF THE INVENTION	7
	4. BRIEF DESCRIPTION OF THE FIGURES	13
	5. DETAILED DESCRIPTION OF THE INVENTION	16
20	5.1 COMPOSITIONS OF THE INVENTION	19
	5.1.1 RECOMBINANT EXPRESSION	20
	5.1.3 ANTIBODIES SPECIFIC FOR α 2M RECEPTOR-HSP COMPLEXES	25
25	5.2 ASSAYS FOR THE IDENTIFICATION OF COMPOUNDS THAT INTERACT WITH THE α 2M RECEPTOR	29
	5.2.1 α 2M RECEPTOR-LIGAND BINDING ASSAYS	32
	5.2.2 α 2M RECEPTOR ACTIVITY ASSAYS	37
	5.2.3 COMPOUNDS THAT CAN BE SCREENED IN ACCORDANCE WITH THE INVENTION	40
30	5.3 IDENTIFICATION OF FRAGMENTS OF THE α 2M RECEPTOR AND/OR α 2M RECEPTOR LIGANDS, SUCH AS HSPS, USEFUL FOR IMMUNOTHERAPY	43
	5.4 DRUG DESIGN	47
	5.5 DIAGNOSTIC USES	49
35	5.6 THERAPEUTIC USES	52
	5.6.1 THERAPEUTIC USE OF IDENTIFIED AGONISTS AND ANTAGONISTS	52

	5.6.2	THERAPEUTIC USE OF THE α 2M RECEPTOR AGAINST CANCER AND INFECTIOUS DISEASES	59
5	5.6.3	GENE REPLACEMENT THERAPY	66
	5.6.4	DELIVERY OF SOLUBLE α 2M RECEPTOR POLYPEPTIDES	67
	5.6.5	DELIVERY OF DOMINANT NEGATIVE MUTANTS	68
	5.6.6	EXTRACORPOREAL METHODS FOR MODULATING THE IMMUNE RESPONSE	68
10	5.7	TARGET AUTOIMMUNE DISEASES	71
	5.8	TARGET INFECTIOUS DISEASES	72
	5.9	TARGET PROLIFERATIVE CELL DISORDERS	73
	5.10	PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION	73
15	5.10.1	EFFECTIVE DOSE	74
	5.10.2	FORMULATIONS AND USE	74
6.		EXAMPLE: IDENTIFICATION OF α 2M RECEPTOR AS AN HSP RECEPTOR	76
20	6.2	MATERIALS AND METHODS	77
	6.3	RESULTS	80